This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Medical Practice  • Conflict of Interest  • Medical Education  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Bruce M. Psaty, MD, PhD

JAMA. 2009;301(14):1477-1479.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

When I was an assistant professor, my previous training had not prepared me for the unexpected attention that 2 articles, both from the same study, were to receive. One article provided evidence that abruptly stopping β-blockers might increase the risk of coronary events.¹ The other suggested that, compared with the use of high-dose diuretics, which is now no longer recommended, the use of β-blockers might be associated with a lower risk of coronary events in hypertensive patients.² While the news media's coverage of the risk study was transient, the pharmaceutical industry had a more sustained interest in the other publication.

My family and I were invited to a first-class resort, where I presented the results at a sponsored conference. Although I lacked both the golf skills and the sense of entitlement to make the most of the holiday, the effort did result in a publication . . . [Full Text of this Article]

Author Affiliations: Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, and Center for Health Studies, Group Health, Seattle.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?